Multicenter Study for the Validation of Willem AI: Aortic StenoSis Early Diagnosis With AI-electrocardiogram Study

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorIdoven 1903 S.L.

About this trial

AoS-SEDAI study is an observational, multicenter, retrospective and prospective clinical study.

This study aims to assess Willem Artificial Intelligence (AI) ability to distinguish between aortic stenosis (AS) and non-AS patients from 12-lead electrocardiogram (ECG) data.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

Age ≥ 18 years;

All available 12-lead ECG with a 10 seconds minimum length on raw data digital format will be included

Available clinical data corresponding to each ECG to confirm patient demographics and Aortic Stenosis diagnosis

Available transthoracic echocardiogram (TTE) within +/- 90 days of each ECG recording

Disqualifiers

None

Trial population

The target population consists of patients under assessment of Aortic Stenosis (AS). Screened patients need to have 12-lead ECG recordings within 90 days of a transthoracic echocardiogram (TTE). In the case of multiple ECGs and TTEs per patient, all of them will be selected and analysed accordingly considering the corresponding PI diagnosis at each time. In the event of a patient with a different diagnosis over time (e.g. non-AS confirmed diagnosis later on diagnosed with AS), multiple timepoint ECGs will be categorized so that the same patient is not included both in the control and in the AS populations. Controls will include non-AS patients with relevant TTE and clinical findings during AS differential diagnosis (such as hypertensive heart disease, structural heart diseases, hypertrophic cardiomyopathy among other cardiomyopathies, mild aortic stenosis, and no significant aortic leaflet calcification).

Trial design

Design model

Case-control

Time perspective

Other

Treatments tested in this trial

  • Willem AI ECG assessment

    Device

    There is no study intervention. The Willem AI platform will assess all study electrocardiograms (ECGs) for the identification of aortic stenosis. Regardless of retrospective or prospective enrollment, Willem output will not be provided to the healthcare professional user for clinical evaluation, and therefore routine practice will not be impacted nor altered.

Treatment groups

5,000 Participants
are divided into 2 treatment groups
Group A: Aortic Stenosis patients1 intervention
Group B: Non-Aortic Stenosis patients (Controls)1 intervention

Trial outcomes

Primary outcomes

1

Willem performance to detect severe Aortic Stenosis

Performance of Willem AI platform to distinguish between severe Aortic Stenosis (AS) patients with confirmed diagnosis and non-AS patients, by means of the following performance metrics: Area Under the Receiver Operating Characteristic curve (AUROC), diagnostic accuracy, sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV). The Standard Of Care (SOC) investigator diagnosis will be used as the ground truth.

Time frame
ECG will be performed at baseline, and ECG analysis by Willem AI will be performed retrospectively throughout the trial, and finalized upon recruitment completion.

Secondary outcomes

1

Willem performance to detect moderate Aortic Stenosis

Performance of Willem AI platform to distinguish between moderate Aortic Stenosis (AS) patients with confirmed diagnosis and non-AS patients, by means of the following performance metrics: Area Under the Receiver Operating Characteristic curve (AUROC), diagnostic accuracy, sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV). The Standard Of Care (SOC) investigator diagnosis will be used as the ground truth.

Time frame
ECG will be performed at baseline, and ECG analysis by Willem AI will be performed retrospectively throughout the trial, and finalized upon recruitment completion.

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.